The ophthalmic disease treatment developer has closed its series A round, which included Boehringer Ingelheim's corporate venturing unit.
Eyevensys, a France-based ophthalmic diseases treatment developer backed by pharmaceutical firm Boehringer Ingelheim, closed its series A round yesterday at €9m ($10m).
The extension was led by healthcare-focused venture capital firm Pontifax Venture Capital. Eyevensys began raising the round in 2013 with an undisclosed amount provided by Boehringer Ingelheim subsidiary Boehringer Ingelheim Venture Investments.
The company revealed in October 2015 that Boehringer Ingelheim’s commitment made it the lead investor in a €7.5m first close which included French state-owned investment bank…
